0000899243-21-000412.txt : 20210105 0000899243-21-000412.hdr.sgml : 20210105 20210105170903 ACCESSION NUMBER: 0000899243-21-000412 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210101 FILED AS OF DATE: 20210105 DATE AS OF CHANGE: 20210105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bailey John E. (Jack) Jr. CENTRAL INDEX KEY: 0001806147 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38096 FILM NUMBER: 21506922 MAIL ADDRESS: STREET 1: C/O G1 THERAPEUTICS, INC. STREET 2: 700 PARK OFFICES DRIVE, SUITE 200 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER NAME: FORMER CONFORMED NAME: Bailey John F. (Jack) Jr. DATE OF NAME CHANGE: 20200310 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: G1 Therapeutics, Inc. CENTRAL INDEX KEY: 0001560241 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263648180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 700 PARK OFFICES DRIVE STREET 2: SUITE 200 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: 919-213-9835 MAIL ADDRESS: STREET 1: 700 PARK OFFICES DRIVE STREET 2: SUITE 200 CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: G-Zero Therapeutics, Inc. DATE OF NAME CHANGE: 20121012 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-01 0 0001560241 G1 Therapeutics, Inc. GTHX 0001806147 Bailey John E. (Jack) Jr. C/O G1 THERAPEUTICS 700 PARK OFFICES DR, SUITE 200 RESEARCH TRIANGLE PARK NC 27709 1 1 0 0 President and CEO Common Stock 2021-01-01 4 A 0 213333 0.00 A 221333 D Stock Options (Right to Buy) 17.99 2021-01-01 4 A 0 320000 0.00 A 2031-01-01 Common Stock 320000 320000 D Represents a restricted stock unit ("RSU") award that vests one-third (1/3rd) on each of the first, second and third anniversaries of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Each RSU represents a contingent right to receive one share of Issuer common stock. Represents 8,000 shares of common stock and 213,333 restricted stock units. The shares underlying this option vest as to 34% of the shares on January 1, 2022, with the remainder vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date. /s/ James Stillman Hanson, attorney-in-fact 2021-01-05